<DOC>
	<DOCNO>NCT01202474</DOCNO>
	<brief_summary>Primary Objective : Evaluate percentage patient achieve glycosylated hemoglobin ( HbA1c ) level &lt; 8 % ( patient 6-12 year old ) HbA1c level &lt; 7.5 % ( patient 13-17 year old ) 6 12 month treatment Secondary Objectives : Change HbA1c level 6 12 month treatment Monthly rate hypoglycaemia/per patient baseline end study Change daily dose glargine glulisine 6 12 month treatment .</brief_summary>
	<brief_title>Apidra Children &amp; Adolescents Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : ChildrenAdolescents Type 1 diabetes Mellitus l ( T1DM ) onger 1 year duration Age 6 17 y.o . With 8 % &lt; HbA1c &lt; 10 % Treated insulin glargine rapid insulin Ability perform self bloodglucose monitoring ( SBGM ) Signed Informed consent . Exclusion criterion : Diabetes Mellitus type 2 ChildrenAdolescents Type 1 diabetes Mellitus previously treat Apidra Hypersensitivity Insulin glulisine Pregnant lactation woman Gestational diabetes mellitus Treatment systemic corticosteroid 1 month prior study entry T1DM complication : already exist active proliferative diabetic retinopathy , define application photocoagulation surgery , 6 month study entry unstable ( rapidly progress ) retinopathy may require photocoagulation surgery study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>